Education
About Us
Working with TipRanks
Follow Us
Merck KGaA (DE:MRK)
XETRA:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€125.70 - €177.00
Previous CloseN/A
Volume8.13K
Average Volume (3M)344.14K
Market Cap
€56.76B
Enterprise Value€77.00B
Total Cash (Recent Filing)€2.22B
Total Debt (Recent Filing)€9.95B
Price to Earnings (P/E)20.4
Beta0.58
Next Earnings
May 15, 2025EPS Estimate
2.26Next Dividend Ex-Date
Apr 28, 2025Dividend Yield1.68%
Share Statistics
EPS (TTM)6.39
Shares Outstanding129,242,250
10 Day Avg. Volume322,625
30 Day Avg. Volume344,144
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€175.86Price Target Upside38.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Merck KGaA News
---
Bulls Say, Bears Say
Bulls Say
Electronics DivisionElectronics recovery is playing out due to AI, improving the profile of the division.
Growth ExpectationsA return to growth in Life Sciences and Process Solutions for the first time in five quarters is expected to give additional confidence to investors on future growth expectations.
ValuationAnalyst re-iterates BUY as MRK is attractively valued compared to its end markets and peers.
Bears Say
Healthcare EBITDAThere is a negative perception surrounding Healthcare-driven EBITDA beats due to cost releases, which investors might see as lower quality compared to topline-driven growth.
Life Sciences VisibilityThere is a clear lack of visibility on FY25 Life Sciences trends, with Bioprocessing numbers below mid-term expectations.
Sales GuidanceThe guidance indicates that the upper end of the sales range is out of reach, aligning with previous messaging but possibly disappointing investors hoping for higher sales figures.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
13.44%
Mutual Funds
<0.01% Other Institutional Investors
71.45% Public Companies and
Individual Investors
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €125.70 and its highest was €177.00 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €56.76B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is May 15, 2025 which is in 43 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on Mar 06, 2025. The company reported €2.07 earnings per share for the quarter, missing the consensus estimate of €2.156 by -€0.086.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.68%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.26.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.07 in its last earnings report, missing expectations of €2.156. Following the earnings report the stock price went up 3.063%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
---
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€175.86 (38.91% Upside)
€175.86 (38.91% Upside)
Insider Transactions
Bought Shares
Worth €1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.17%
12-Months-Change
Fundamentals
Return on Equity
9.81%
Trailing 12-Months
Asset Growth
6.05%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In its performance materials segment, the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
---
MRK Stock 12 Month Forecast
Average Price Target
€175.86
▲(38.91% Upside)
Technical Analysis
Bayer
―
Fresenius Medical Care AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
Rheinmetall
―
Sartorius
―
Best Analysts Covering MRK
1 Year
1 Year Success Rate
19/28 ratings generated profit
1 Year Average Return
+12.67%
reiterated a buy rating 4 months ago
Copying Peter Spengler's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +12.67% per trade.
---